Testosterone cypionate

Generic Name: Testosterone cypionate

Brand Names: Depo-testosterone

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₄₀O_₃

CAS Number: 58-20-8

Unique Ingredient Identifier: M0XW1UBI14

Background: Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester. Its benefit compared to other testosterone derivatives is the slow rate of release after injection and longer half-life. It was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979.

Indication: Testosterone cypionate is used in males that present conditions derived from a deficiency or absence of endogenous testosterone. These conditions are 1) primary hypogonadism, defined as the testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome or orchidectomy; and 2) hypogonadotropic hypogonadism characterized by id...

Associated Conditions: Hypergonadotropic Hypogonadism, Hypogonadotrophic Hypogonadism

Associated Therapies: -

Clinical Trials

Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Testosterone cypionate

First Posted Date: 2020-06-11

Last Posted Date: 2022-08-03

Lead Sponsor: Hospital Sirio-Libanes

Target Recruit Count: 20

Registration Number: NCT04424654

Locations: 🇧🇷
Hospital Sirio-Libanes, São Paulo, Brazil
🇧🇷
Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

Phase 2

Recruiting

Conditions: Castration Resistant Metastatic Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Testosterone cypionate
Drug: Testosterone enanthate

First Posted Date: 2020-04-27

Last Posted Date: 2024-12-04

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 150

Registration Number: NCT04363164

Locations: 🇺🇸
Dana-Faber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Washington/Fred Hutchinson Cancer Center, Seattle, Washington, United States
🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

and more 3 locations

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

Phase 2

Withdrawn

Conditions: Rotator Cuff Tears

Interventions: Drug: Placebos
Drug: Testosterone cypionate

First Posted Date: 2020-04-14

Last Posted Date: 2022-03-15

Lead Sponsor: Orthopedic Institute, Sioux Falls, SD

Registration Number: NCT04345666

Locations: 🇺🇸
Orthopedic Institute, Sioux Falls, South Dakota, United States

COMbination of Bipolar Androgen Therapy and Nivolumab

Phase 2

Completed

Conditions: Prostate Cancer
Castration-resistant Prostate Cancer
Metastatic Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Nivolumab

First Posted Date: 2018-06-13

Last Posted Date: 2024-02-20

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 45

Registration Number: NCT03554317

Locations: 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Castration-Resistant Prostate Carcinoma
Prostate Adenocarcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Olaparib
Other: Quality-of-Life Assessment
Other: Survey Administration
Drug: Testosterone Enanthate
Drug: Testosterone Cypionate

First Posted Date: 2018-05-04

Last Posted Date: 2024-05-02

Lead Sponsor: University of Washington

Target Recruit Count: 36

Registration Number: NCT03516812

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness

Phase 2

Conditions: Critical Illness Polyneuropathies

Interventions: Drug: Testosterone cypionate
Other: Standard nutrition and physical therapy at ICU

First Posted Date: 2017-02-01

Last Posted Date: 2017-02-01

Lead Sponsor: Hospital de Clinicas de Porto Alegre

Target Recruit Count: 30

Registration Number: NCT03038919

Locations: 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil

Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Procedure: Bone marrow transplantation
Drug: Cytoxan
Drug: testosterone cypionate

First Posted Date: 2016-12-16

Last Posted Date: 2024-02-13

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 3

Registration Number: NCT02995330

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance

Phase 2

Completed

Conditions: Castration Resistant Metastatic Prostate Cancer

Interventions: Drug: Enzalutamide
Drug: Testosterone cypionate
Drug: Testosterone Enanthate

First Posted Date: 2014-11-10

Last Posted Date: 2020-11-06

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 222

Registration Number: NCT02286921

Locations: 🇺🇸
Piedmont Cancer Institute, Atlanta, Georgia, United States
🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸
SKCCC at Johns Hopkins, Baltimore, Maryland, United States

and more 14 locations

RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Testosterone Enanthate
Drug: Enzalutamide
Drug: Abiraterone acetate

First Posted Date: 2014-03-18

Last Posted Date: 2022-06-27

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 112

Registration Number: NCT02090114

Locations: 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

Phase 2

Completed

Conditions: Recurrent Prostate Cancer

Interventions: Drug: Testosterone cypionate
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2012-12-17

Last Posted Date: 2016-12-05

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 33

Registration Number: NCT01750398

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy